Source: Eur Respir Mon; 2009: 46: 47–66
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Nukiwa. The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes. Eur Respir Mon; 2009: 46: 47–66

Member's Comments

No comment yet.

Related content which might interest you: The role of cell lines in modelling the type II pneumocyte in interstitial lung disease Source: Virtual Congress 2020 – Human ex vivo models of interstitial lung disease Year: 2020 Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 The role of calcium metabolism assessment in the clinical setting of interstitial lung diseases Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Identifying pulmonary hypertension in newly recognized interstitial lung diseases – a role of new scoring system Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Evidence of type II pneumocyte apoptosis in the murine model of Hermansky-Pudlak-syndrome associated interstitial pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 The role of macrophages in interstitial lung diseases Source: Eur Respir Rev, 26 (145) 170009; 10.1183/16000617.0009-2017 Year: 2017 The effectiveness of pulmonary rehabilitation in interstitial lung diseases in terms of functional markers Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Circulating fibrocytes and collagen turnover products in UIP: marker of disease activity and prognostic tool? Source: Eur Respir J 2007; 30: Suppl. 51, 118s Year: 2007 Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020 Year: 2020 Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020 Year: 2020 The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006 Progress in the pathology of diffuse lung disease in infancy: changing concepts and diagnostic challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=21 Year: 2007 Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease? Source: International Congress 2016 – Connective tissue disorders Year: 2016 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Issues other than tissue: non-invasive biomarkers of early stage lung cancer Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules? Year: 2020 Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 alpha-v-beta-6 integrin may be a potential prognostic biomarker in interstitial lung disease Source: Eur Respir J 2015; 46: 486-494 Year: 2015